Lixisenatide for type 2 diabetes mellitus

被引：74

作者：

Christensen, Mikkel ^{[1
]}

Knop, Filip K. ^{[1
]}

Vilsboll, Tina ^{[1
]}

Holst, Jens J. ^{[2
]}

机构：

[1] Univ Copenhagen, Gentofte Hosp, Diabet Res Div, Dept Internal Med F, DK-2900 Hellerup, Denmark

[2] Univ Copenhagen, Panum Inst, Dept Biomed Sci, DK-2200 Copenhagen N, Denmark

来源：

EXPERT OPINION ON INVESTIGATIONAL DRUGS | 2011年 / 20卷 / 04期

关键词：

AVE0010; GETGOAL; GLP-1; incretin mimetics; lixisenatide; type; 2; diabetes; GLUCAGON-LIKE PEPTIDE-1; RECEPTOR AGONIST AVE0010; BETA-CELL FUNCTION; INSULIN-SECRETION; DOUBLE-BLIND; OPEN-LABEL; EXENATIDE; HEALTHY; HYPERGLYCEMIA; DYSFUNCTION;

D O I：

10.1517/13543784.2011.562191

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Areas covered: Pharmacological, preclinical and clinical evidence demonstrating the applicability of lixisenatide for the treatment of T2DM are reviewed. Available data and pending clinical development are summarized, critically appraised and compared to competitor drugs. The most relevant papers and meeting abstracts published up to November 2010 are used as sources for this review. Expert opinion: Efficacy and safety in T2DM are demonstrated with lixisenatide in monotherapy and in combination with metformin. However, limited data with the intended once-daily 20 mu mu g subcutaneous dosing necessitate further evaluation of lixisenatide as add-on to various antidiabetic treatments. It remains to be established whether the slightly differing chemical properties compared to other GLP-1 receptor agonists including a rather short duration of action will be a disadvantage or maybe even an advantage, for example, when combined with long-acting insulin.

引用

页码：549 / 557

页数：9

共 49 条

[41] Enhanced protection against cytokine- and fatty acid-induced apoptosis in pancreatic beta cells by combined treatment with glucagon-like peptide-1 receptor agonists and insulin analogues [J].

Tews, D. ;

Werner, U. ;

Eckel, J. .

HORMONE AND METABOLIC RESEARCH, 2008, 40 (03) :172-180

[42] Glucagon-like peptide 1 receptor agonist ZP10A increases insulin mRNA expression and prevents diabetic progression in db/db mice [J].

Thorkildsen, C ;

Neve, S ;

Larsen, BD ;

Meier, E ;

Petersen, JS .

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2003, 307 (02) :490-496

[43] SIGNAL-TRANSDUCTION OF THE GLP-1-RECEPTOR CLONED FROM A HUMAN INSULINOMA [J].

VANEYLL, B ;

LANKATBUTTGEREIT, B ;

BODE, HP ;

GOKE, R ;

GOKE, B .

FEBS LETTERS, 1994, 348 (01) :7-13

[44] Evaluation of β-cell secretory capacity using glucagon-like peptide 1 [J].

Vilsboll, T ;

Toft-Nielsen, MB ;

Krarup, T ;

Madsbad, S ;

Dinesen, B ;

Holst, JJ .

DIABETES CARE, 2000, 23 (06) :807-812

[45]

WARD W K, 1986, Diabetes Metabolism Reviews, V2, P297

[46]

Werner U, 2008, DIABETES, V57, pA3

[47]

Werner U, 2007, DIABETES, V56, pA129

[48] Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes [J].

Werner, Ulrich ;

Haschke, Guido ;

Herling, Andreas W. ;

Kramer, Werner .

REGULATORY PEPTIDES, 2010, 164 (2-3) :58-64

[49] Global prevalence of diabetes - Estimates for the year 2000 and projections for 2030 [J].

Wild, S ;

Roglic, G ;

Green, A ;

Sicree, R ;

King, H .

DIABETES CARE, 2004, 27 (05) :1047-1053

← 1 2 3 4 5 →